Through years of development, our team has built a comprehensive oncology portfolio that covers the full cycle of cancer management, addressing needs and challenges from early screening, diagnosis & monitoring, and biopharma development services. While continuously carrying out scientific and technological innovation, we efficiently transform these breakthroughs into clinical applications, which have served tens of thousands of patients, and dozens of scientific research institutions and pharmaceutical enterprises across China. See our journey below.



Genetron Health begins strategic partnership with Chia Tai Tianqing (CTTQ) Pharmaceutical Group.


Genetron Health releases new prospective cohort study data of HCCscreen for early liver cancer screening.


Genetron Health receives CE Mark for 8-Gene Lung Cancer Assay.


Genetron Health receives full marks under the NCCL external quality assessment of NGS-based comprehensive genomic profiling for solid tumors, ranking first among the 63 laboratories nationwide.


Genetron Health and Fosun Pharma announce exclusive partnership to commercialize Seq-MRD® in China.


Genetron Health’s early precision lung cancer diagnosis and treatment project, a joint initiative with the West China Hospital of Sichuan University, won the second prize of China’s National Science and Technology Progress Award.


Genetron Health signed a collaboration agreement with AstraZeneca R&D China for the joint development in China of NGS-based tumor-informed (personalized) MRD tests for various solid tumor types.


Genetron Health’s liver cancer screening results and technology findings are included in the expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma – submitted by the Infectious Disease Prevention and Control Division of the Chinese Preventive Medicine Association.


Genetron Health’s multi-gene mutation detection kit Onco PanScan obtains CE Mark


Laboratory in Maryland is established